Iron Gate Global Advisors’s Galectin Therapeutics GALT Stock Holding History

Iron Gate Global Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-17,090	Closed	-$52K	–	102
2020 Q2	$52K	Hold	17,090	–	–	0.03%	85
2020 Q1	$33K	Hold	17,090	–	–	0.02%	57
2019 Q4	$49K	Buy	+17,090	New	+$59.4K	0.03%	68
2019 Q3	–	Sell	-17,090	Closed	-$71K	–	74
2019 Q2	$71K	Buy	+17,090	New	+$74K	0.05%	67
2019 Q1	–	Sell	-17,090	Closed	-$59K	–	78
2018 Q4	$59K	Hold	17,090	–	–	0.04%	64
2018 Q3	$79K	Buy	17,090 +16,400	+2,377%	+$90.2K	0.05%	103
2018 Q2	$4K	Buy	+690	New	+$3.36K	﹤0.01%	179

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Iron Gate Global Advisors's GALT Position: Q3 2020 in Review

Iron Gate Global Advisors sold out of Galectin Therapeutics (GALT) in Q3 2020, closing a stake of 17,090 shares — an estimated $52K sold.

Iron Gate Global Advisors first reported a position in GALT in Q2 2018 and held it in 7 quarters. The position peaked at $79K in Q3 2018. 71 funds tracked by Wall St. Rank hold GALT as of Q3 2020.

Iron Gate Global Advisors reported no remaining Galectin Therapeutics position as of Q3 2020 after selling out during the quarter.
Iron Gate Global Advisors sold 17,090 Galectin Therapeutics shares in Q3 2020, an estimated $52K.
Iron Gate Global Advisors first reported a position in Galectin Therapeutics in Q2 2018 and held it in 7 quarters.
Iron Gate Global Advisors's Galectin Therapeutics position peaked at $79K in Q3 2018.
71 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2020.

Based on Iron Gate Global Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.